Concepedia

Piero Reynolds

PR

Statistics

Publications

7

Citations

1.5K

H-Index

7

Active since

2005

Affiliations

University of Oxford(Current)

University of Manchester

King's College London

NIHR Oxford Musculoskeletal Biomedical Research Centre

Newcastle University

Piero Reynolds is an author at University of Oxford specializing in life sciences, rheumatology, and immunology.

Publications per year

2005–2024

7

Publications

7

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2022 · 384 citations · Full text

, , +14

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

Frances Humby, Patrick Durez, Maya H Buch et al. · The Lancet · 2021 · 315 citations · Full text

, , +17

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 291 citations · Full text

, , +13

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Felice Rivellese, Anna E. A. Surace, Katriona Goldmann et al. · Nature Medicine · 2022 · 279 citations · Full text

, , +17

Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Andrew P. Cope, Marianna Jasenecova, Joana C. Vasconcelos et al. · The Lancet · 2024 · 160 citations · Full text

, , +17

1–5 of 7